Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
377
Employees377
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
377
Employees377

NTLA Key Statistics

Market cap
1.58B
Market cap1.58B
Price-Earnings ratio
-3.33
Price-Earnings ratio-3.33
Dividend yield
Dividend yield
Average volume
5.23M
Average volume5.23M
High today
$13.66
High today$13.66
Low today
$12.80
Low today$12.80
Open price
$13.12
Open price$13.12
Volume
3.70M
Volume3.70M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$5.90
52 Week low$5.90

Stock Snapshot

As of today, Intellia Therapeutics(NTLA) shares are valued at $13.33. The company's market cap stands at 1.58B, with a P/E ratio of -3.33.

During the trading session on 2026-03-16, Intellia Therapeutics(NTLA) shares reached a daily high of $13.66 and a low of $12.80. At a current price of $13.33, the stock is +4.2% higher than the low and still -2.4% under the high.

Trading volume for Intellia Therapeutics(NTLA) stock has reached 3.7M, versus its average volume of 5.23M.

Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.

Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.

NTLA News

Simply Wall St 7d
Is Intellia Therapeutics Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?

In recent weeks, Intellia Therapeutics reported long-term Phase 1/2 data for its CRISPR-based HAE candidate lonvoguran ziclumeran and regained FDA clearance to...

Is Intellia Therapeutics Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?

Analyst ratings

54%

of 24 ratings
Buy
54.2%
Hold
37.5%
Sell
8.3%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.